Skip to Content
Merck
  • Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Molecular and cellular endocrinology (2015-09-24)
Katja Kiseljak-Vassiliades, Mei Xu, Taylor S Mills, Elizabeth E Smith, Lori J Silveira, Kevin O Lillehei, Janice M Kerr, B K Kleinschmidt-DeMasters, Margaret E Wierman
ABSTRACT

The aim of this study was to examine whether differential expression of somatostatin receptors (SSTR) 1-5 and downstream effectors are different in densely (DG) and sparsely (SG) granulated histological growth hormone (GH) pituitary tumor subtypes. The study included 33 acromegalic patients with 23 DG and 10 SG tumors. SSTR1-5 were measured by qPCR and immunoblotting. Signaling candidates downstream of SSTR2 were also assessed. SSTR2 mRNA and protein levels were significantly higher in DG compared to SG tumors. Downstream of SSTR2, p27(kip1) was decreased (2.6-fold) in SG compared to DG tumors, suggesting a potential mechanism of SSA resistance in SG tumors with intact SSTR2 expression. Re-expression of E-cadherin in GH pituitary cell increased p27(kip1) levels. Histological subtyping correlated with SSTR2, E cadherin and p27(kip) protein levels and these may serve as useful biomarkers in GH tumors to predict behavior and response to therapy with SSA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-p27Kip1 antibody produced in mouse, clone DCS-72, ascites fluid